XBIOTECH INC. (NASDAQ:XBIT) Files An 8-K Other Events
Item 8.01. Other Events.
Information on First Quarter 2017 Business Update Call
On April 28, 2017, XBiotech Inc. (the Company) issued a press
release announcing it will host a conference call and live audio
webcast on Thursday, May 4, 2017, at 8:30 a.m. Eastern Time, to
provide an overview of its corporate and clinical activities. The
call will encompass developments during the first quarter ended
March 31, 2017.
Details of the call are as follows:
Conference Call Information: Interested
participants and investors may access the conference call by
dialing:
- 1 (844) 249-9385 (U.S.)
- 1 (270) 823-1533 (International)
- Conference ID: 15848733
A live audio webcast will also be accessible via the Investors
section of the XBiotech website www.xbiotech.com. The
webcast replay will remain available for 90 days.
A telephonic replay of the conference call can be accessed by
dialing 1 (855) 859-2056 (U.S.) or 1 (404) 537-3406, and
providing the Conference ID: 15848733. The telephonic replay will
be available for 24 hours beginning at 11:29 p.m. Eastern Time on
May 4, 2017.
A copy of the press release issued in connection with the
announcement is filed as Exhibit 99.1 to this Current Report on
Form 8-K.
This Form 8-K and the related press release contain
forward-looking statements, including declarations regarding
management’s beliefs and expectations, that involve substantial
risks and uncertainties. In some cases, you can identify
forward-looking statements by terminology such as may, will,
should, would, could, expects, plans, contemplate, anticipates,
believes, estimates, predicts, projects, intend or continue or
the negative of such terms or other comparable terminology,
although not all forward-looking statements contain these
identifying words. Forward-looking statements are subject to
inherent risks and uncertainties in predicting future results and
conditions that could cause the actual results to differ
materially from those projected in these forward-looking
statements. These risks and uncertainties are subject to
the disclosures set forth in “Risk Factors” in our SEC
filings.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press Release of XBiotech Inc., Issued April 28, 2017. |
About XBIOTECH INC. (NASDAQ:XBIT)
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody Xilonix is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a). The Company completed a Phase I and II clinical trial for MABp1 as a treatment for cancer at MD Anderson Cancer Center. The Company is also investigating MABp1 in clinical trials for other indications, including vascular disease, type II diabetes, acne and psoriasis. XBIOTECH INC. (NASDAQ:XBIT) Recent Trading Information
XBIOTECH INC. (NASDAQ:XBIT) closed its last trading session down -0.02 at 10.86 with 429,421 shares trading hands.
